Ajay K. Nooka named associate director for clinical research at Winship

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial. The median PFS was 39.1 months in the osimertinib group, compared to 5.6 months with the placebo group.

June 07, 2024

Vol.50 No.23

By Jacquelyn Cobb and McKenzie Prillaman

Guest Editorial

Emory Midtown: Architects’ reflections on designing a cancer care center that has never been seen or imagined

As architects, we welcomed the challenge set forth by Emory Healthcare and the Emory Woodruff Health Sciences Center to build a new cancer care center for Winship Cancer Institute of Emory University.

January 12, 2024

Vol.50 No.02

By Anthony Treu and Gil May

In Brief

Walter Curran named chief of Piedmont Oncology Institute

Walter J. Curran Jr., former executive director of Winship Cancer Institute of Emory University, was named chief of Piedmont Oncology Institute (Piedmont Oncology), effective Jan. 9.

December 08, 2023

Vol.49 No.45

In Brief

Emory Winship receives $24.8M from ARPA-H for mRNA therapeutics project

Winship Cancer Institute of Emory University received a three-year, $24.8 million cooperative agreement from the Advanced Research Projects Agency for Health to lead the CUREIT program: “Curing the Uncurable via RNA-Encoded Immunogene Tuning.”

September 15, 2023

Vol.49 No.34

In Brief

Winship’s Suresh Ramalingam receives IASLC award for contributions to thoracic cancer research

Suresh Ramalingam, executive director of Winship Cancer Institute of Emory University, was awarded the Paul A. Bunn, Jr. Scientific Award Sept. 9 at the 2023 IASLC World Conference on Lung Cancer.

September 15, 2023

Vol.49 No.34